Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ATHS
MCID: ATH013
MIFTS: 64

Atherosclerosis Susceptibility (ATHS)

Categories: Blood diseases, Cardiovascular diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Atherosclerosis Susceptibility

About this section

MalaCards integrated aliases for Atherosclerosis Susceptibility:

Name: Atherosclerosis Susceptibility 57
Atherosclerosis 57 11 75 28 53 41 43 14 63 16 71 31
Atherosclerosis, Susceptibility to 57 12 5
Atherogenic Lipoprotein Phenotype 57
Arteriosclerosis 71
Aths 57
Alp 57

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:1936
OMIM® 57 108725
ICD9CM 34 440
MeSH 43 D050197
NCIt 49 C35768
SNOMED-CT 68 155414001
ICD10 31 I70
MedGen 40 C1531719
SNOMED-CT via HPO 69 190785000 22298006
UMLS 71 C0003850 C0004153
Sources

Summaries for Atherosclerosis Susceptibility

About this section

MedlinePlus: 41 Atherosclerosis is a disease in which plaque builds up inside your arteries. Plaque is a sticky substance made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. That limits the flow of oxygen-rich blood to your body. Atherosclerosis can lead to serious problems, including: Coronary artery disease. These arteries supply blood to your heart. When they are blocked, you can suffer angina or a heart attack. Carotid artery disease. These arteries supply blood to your brain. When they are blocked you can suffer a stroke. Peripheral arterial disease. These arteries are in your arms, legs and pelvis. When they are blocked, you can suffer from numbness, pain and sometimes infections. Atherosclerosis usually doesn't cause symptoms until it severely narrows or totally blocks an artery. Many people don't know they have it until they have a medical emergency. A physical exam, imaging, and other diagnostic tests can tell if you have it. Medicines can slow the progress of plaque buildup. Your doctor may also recommend procedures such as angioplasty to open the arteries, or surgery on the coronary or carotid arteries. Lifestyle changes can also help. These include following a healthy diet, getting regular exercise, maintaining a healthy weight, quitting smoking, and managing stress. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Atherosclerosis Susceptibility, also known as atherosclerosis, is related to cerebral atherosclerosis and generalized atherosclerosis, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Atherosclerosis Susceptibility is ATHS (Atherosclerosis Susceptibility (Lipoprotein Associated)), and among its related pathways/superpathways are Plasma lipoprotein assembly, remodeling, and clearance and Interleukin-4 and Interleukin-13 signaling. The drugs Cilostazol and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include Heart, and related phenotypes are hypertriglyceridemia and myocardial infarction

OMIM®: 57 The atherogenic lipoprotein phenotype (ALP) is a common heritable trait characterized by a preponderance of small, dense low density lipoprotein (LDL) particles (subclass pattern B), increased levels of triglyceride-rich lipoproteins, reduction in high density lipoprotein, and a 3-fold increased risk of myocardial infarction (summary by Nishina et al., 1992). The so-called atherogenic lipoprotein phenotype was shown by Austin et al. (1988) to be independently associated with an increased risk for coronary artery disease. Allayee et al. (1998) concluded, furthermore, that there is a genetically based association between familial combined hyperlipidemia (FCHL; 144250) and small, dense LDL particles and that the genetic determinants for LDL particle size are shared, at least in part, among FCHL families and the more general population at risk for coronary artery disease. Juo et al. (1998) concluded from a bivariate segregation analysis of small, dense LDL particles and elevated apolipoprotein B levels (APOB; 107730), which are commonly found together in members of FCHL families, that the 2 traits share a common major gene plus individual polygenic components. The common major gene was estimated to explain 37% of the variance of adjusted LDL particle size and 23% of the variance of adjusted apoB levels. (108725) (Updated 08-Dec-2022)

PubMed Health : 63 Atherosclerosis: Atherosclerosis (ath-er-o-skler-O-sis) is a disease in which plaque (plak) builds up inside your arteries. Arteries are blood vessels that carry oxygen-rich blood to your heart and other parts of your body. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. Atherosclerosis can lead to serious problems, including heart attack, stroke, or even death.

Wikipedia: 75 Atherosclerosis is a pattern of the disease arteriosclerosis in which the wall of the artery develops... more...
Sources

Related Diseases for Atherosclerosis Susceptibility

About this section

Diseases related to Atherosclerosis Susceptibility via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1437)
# Related Disease Score Top Affiliating Genes
1 cerebral atherosclerosis 33.2 CRP APOE APOB APOA1
2 generalized atherosclerosis 32.8 INS CRP APOE APOB
3 cerebrovascular disease 32.6 INS CRP APOE APOB APOA1
4 carotid stenosis 32.5 VCAM1 CRP CDKN2B-AS1 APOE
5 angina pectoris 32.5 INS CRP APOA1
6 sitosterolemia 32.4 APOE APOB APOA1 ABCA1
7 carotid artery disease 32.4 VCAM1 INS CRP APOE APOB APOA1
8 hyperhomocysteinemia 32.4 VCAM1 H19 CRP CCL2 APOE
9 myocardial infarction 32.3 VCAM1 TLR4 INS CRP CDKN2B-AS1 CCL2
10 tangier disease 32.2 APOE APOB APOA1 ABCA1
11 lecithin:cholesterol acyltransferase deficiency 32.1 APOE APOB APOA1
12 aortic aneurysm, familial thoracic 1 32.1 VCAM1 TP53COR1 CRP CDKN2B-AS1 CCL2 APOE
13 systemic lupus erythematosus 32.0 VCAM1 TLR4 INS CRP CCL2 APOE
14 cardiovascular system disease 32.0 VCAM1 TLR4 INS CRP CDKN2B-AS1 CCL2
15 hypercholesterolemia, familial, 2 32.0 APOE APOB
16 chlamydia 32.0 TLR4 CRP CCL2
17 familial hypercholesterolemia 32.0 INS APOE APOB APOA1 ANGPTL3 ABCA1
18 chronic kidney disease 31.9 TUG1 INS CRP APOB APOA1
19 diabetes mellitus 31.9 VCAM1 TUG1 TLR4 INS CRP CDKN2B-AS1
20 aortic aneurysm 31.9 CRP CDKN2B-AS1 CCL2 APOE
21 familial hyperlipidemia 31.8 INS CRP APOE APOB APOA1 ANGPTL3
22 peripheral artery disease 31.8 VCAM1 INS CRP CDKN2B-AS1 CCL2 APOE
23 hypertension, essential 31.8 VCAM1 TLR4 INS CRP CDKN2B-AS1 CCL2
24 prediabetes syndrome 31.8 INS CRP APOB APOA1
25 intermediate coronary syndrome 31.7 VCAM1 INS CRP APOB APOA1
26 transient cerebral ischemia 31.7 INS CRP APOE
27 autoimmune disease 31.7 VCAM1 TLR4 INS CRP CCL2
28 acute myocardial infarction 31.7 INS CRP CDKN2B-AS1 APOB APOA1
29 apnea, obstructive sleep 31.7 INS CRP APOE
30 aortic aneurysm, familial abdominal, 1 31.7 VCAM1 H19 CRP CDKN2B-AS1 CCL2 APOE
31 body mass index quantitative trait locus 11 31.7 VCAM1 TLR4 INS H19 CRP CCL2
32 sleep apnea 31.7 VCAM1 INS CRP CCL2 APOE APOB
33 glucose intolerance 31.5 VCAM1 INS CRP CCL2 APOA1
34 antiphospholipid syndrome 31.5 VCAM1 TLR4 CRP
35 microvascular complications of diabetes 1 31.5 VCAM1 INS CCL2
36 non-alcoholic steatohepatitis 31.4 TLR4 INS CCL2 APOB
37 hypoalphalipoproteinemia, primary, 1 31.4 APOE APOB APOA1 ANGPTL3 ABCA1
38 nonobstructive coronary artery disease 31.4 INS CRP CDKN2B-AS1 APOE APOB APOA1
39 alzheimer disease, familial, 1 31.4 TLR4 INS CDKN2B-AS1 CCL2 APOE APOB
40 amyloidosis 31.3 INS CRP APOE APOA1
41 hyperlipidemia, familial combined, 3 31.3 INS APOE APOB APOA1 ANGPTL3
42 lipid storage disease 31.2 TLR4 INS CRP CCL2 APOB
43 macular degeneration, age-related, 1 31.2 INS CRP CCL2 APOE APOB ABCA1
44 xanthomatosis 31.2 APOE APOB ABCA1
45 hypolipoproteinemia 31.2 APOE APOB APOA1 ANGPTL3 ABCA1
46 lipoprotein quantitative trait locus 31.2 VCAM1 TLR4 INS H19 CRP CDKN2B-AS1
47 pre-eclampsia 31.2 VCAM1 TUG1 TLR4 INS H19 CRP
48 hyperlipoproteinemia, type iii 31.2 APOE APOB APOA1
49 kawasaki disease 31.1 VCAM1 CRP CCL2
50 migraine with or without aura 1 31.1 INS CRP CCL2 APOE

Graphical network of the top 20 diseases related to Atherosclerosis Susceptibility:



Diseases related to Atherosclerosis Susceptibility
Sources

Symptoms & Phenotypes for Atherosclerosis Susceptibility

About this section

Human phenotypes related to Atherosclerosis Susceptibility:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertriglyceridemia 30 HP:0002155
2 myocardial infarction 30 HP:0001658
3 decreased hdl cholesterol concentration 30 HP:0003233

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Cardiac:
increased myocardial infarction risk

Lab:
preponderance of small, dense low density lipoprotein (ldl) particles (subclass pattern b)
increased triglyceride-rich lipoproteins
reduced high density lipoprotein

Clinical features from OMIM®:

108725 (Updated 08-Dec-2022)

UMLS symptoms related to Atherosclerosis Susceptibility:


angina pectoris; chest pain; edema

GenomeRNAi Phenotypes related to Atherosclerosis Susceptibility according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased free cholesterol GR00340-A-2 8.8 APOA1 APOB APOE

MGI Mouse Phenotypes related to Atherosclerosis Susceptibility:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.23 ABCA1 ANGPTL3 APOA1 APOB APOE CCL2
Sources

Drugs & Therapeutics for Atherosclerosis Susceptibility

About this section

PubMed Health treatment related to Atherosclerosis Susceptibility: 63

Treatments for atherosclerosis may include lifestyle changes, medicines, and medical procedures or surgery . The goals of treatment include: Relieving symptoms Reducing risk factors in an effort to slow or stop the buildup of plaque Lowering the risk of blood clots forming Widening or bypassing plaque -clogged arteries Preventing atherosclerosis -related diseases

Drugs for Atherosclerosis Susceptibility (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 549)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
3
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
4
Dapagliflozin Approved Phase 4 461432-26-8 9887712
5
Alogliptin Approved Phase 4 850649-61-5 11450633
6
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
7
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
8
Saxagliptin Approved Phase 4 361442-04-8 11243969
9
Glimepiride Approved Phase 4 93479-97-1 3476
10
Pitavastatin Approved Phase 4 147511-69-1 5282452
11
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
12
Isosorbide dinitrate Approved, Investigational Phase 4 87-33-2 3780 6883
13
Isosorbide Approved, Investigational Phase 4 652-67-5 99937 12597
14
Nitric Oxide Approved Phase 4 10102-43-9 145068
15
Ramipril Approved Phase 4 87333-19-5 5362129
16
Bisoprolol Approved Phase 4 66722-44-9 2405
17
Pravastatin Approved Phase 4 81093-37-0 54687
18
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
19
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
20
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
21
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
22
Sodium fluoride Approved Phase 4 7681-49-4
23
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
24
Argatroban Approved, Investigational Phase 4 74863-84-6 152951 92722
25
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
26
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
27
Insulin detemir Approved Phase 4 169148-63-4 16137271
28
Dipyridamole Approved Phase 4 58-32-2 3108
29
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
30
Caffeine Approved Phase 4 58-08-2 2519
31
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
32
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
33
Dextromethorphan Approved Phase 4 125-71-3 5362449 5360696
34
Adalimumab Approved, Experimental Phase 4 331731-18-1
35
Calcipotriol Approved Phase 4 112965-21-6 5288783
36
Anthralin Approved Phase 4 1143-38-0 2202
37
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
38
Plasminogen Approved Phase 4 9001-91-6
39
Sevelamer Approved Phase 4 52757-95-6 3085017
40
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
41
Molsidomine Approved, Investigational Phase 4 25717-80-0 4238
42
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
43
Remifentanil Approved Phase 4 132875-61-7 60815
44
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
45
Acetaminophen Approved Phase 4 103-90-2 1983
46
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
47
Calcium acetate Approved, Investigational Phase 4 62-54-4
48
Probucol Approved, Investigational Phase 4 23288-49-5 4912
49
Iron Approved Phase 4 7439-89-6 29936
50
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 1616)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
2 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
3 Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis. Unknown status NCT00711984 Phase 4
4 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
5 The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients Unknown status NCT00470808 Phase 4 POMx
6 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
7 The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study Unknown status NCT01831869 Phase 4 L-thyroxine
8 Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis Unknown status NCT00640744 Phase 4 Atorvastatin
9 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
10 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
11 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) Unknown status NCT00217178 Phase 4 Vitamins: Folic acid, B6, B12
12 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
13 Treatment of Coronary Atherosclerosis and Calcification by Insulin Sensitizers in Insulin-Resistant Patients: Evaluated by EBCT, 16-Slice MDCT Coronary Angiography/Scanning, and Intravascular Ultrasound Unknown status NCT00155350 Phase 4 pioglitazone
14 Effects of SGLT2 Inhibitor on Markers of Inflammation, Atherosclerosis and Left Ventricular Strain in Diabetic Patients With Coronary Artery Disease Unknown status NCT03398577 Phase 4 Dapagliflozin 10 MG [Farxiga];Placebo Oral Tablet
15 Comparison of Anti-inflammatory Status Linked to Atherosclerosis Formation/Progression Among Diabetes Mellitus Type 2 Patients Under Combined Pharmacological Therapy Unknown status NCT04392557 Phase 4 Metformin / alogliptin Oral Product;Metformin / Pioglitazone Pill;triple therapy
16 Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women Unknown status NCT00154180 Phase 4 Conjugated equine estrogens 0.45 mg/day;Transdermal estradiol, 50 mcg/day;Micronized progesterone, 200 mg/day x 12 d/month;CEE , progesterone, estradiol patch or placebo for each;CEE, progesterone, transdermal patch or the placebo
17 The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Atherosclerosis Unknown status NCT00963222 Phase 4 vitamin A;placebo
18 Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
19 Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM Unknown status NCT02162550 Phase 4 Bydureon;placebo
20 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques. Unknown status NCT01773512 Phase 4 Rosuvastatin
21 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
22 Pilot Prospective Study of Two Methods of Revascularization of the Superficial Femoral Artery: Stenting in the Superficial Femoral Artery, and Stenting of the Superficial Femoral Artery, Supplemented by Fasciotomy in Hunter Channel in Patients With Steno-occlusive Lesions of Femoral-popliteal Segment TASC C, D Unknown status NCT02590471 Phase 4
23 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
24 Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome Unknown status NCT02049229 Phase 4
25 Effect of Sarilumab Therapy on Atherosclerotic Disease Assessed by Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Rheumatoid Arthritis Unknown status NCT04350216 Phase 4 Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
26 Effect of Hydroxychloroquine on Endothelial Function: a Clinical Trial Unknown status NCT04161339 Phase 4 Hydroxychloroquine;Placebo oral tablet
27 Cholesterol Reduction With Evolocumab and Coronary MicrovascuLar Function and Coronary Flow: The CHORAL Flow Study Unknown status NCT04073134 Phase 4 Placebo
28 The Efficacy of Glycemic Control With Continuous Glucose Monitoring on Atheroma Progression: Rationale and Design of the Observation of Coronary Atheroma Progression Under Continuous Glucose Monitoring Guidance in Patients With Type 2 Diabetes Mellitus Unknown status NCT04559191 Phase 4
29 Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab - a Pilot Study Unknown status NCT02992301 Phase 4 Alirocumab
30 The Effect of Dates on Plasma Lipids, Oxidative Stress and the Atherogenicity of Serum in Healthy Adults Unknown status NCT00750789 Phase 4
31 Erythrocyte-Mediated Drug Delivery for the Prevention of Restenosis After Coronary Artery Stent Implantation:TROY-Study Unknown status NCT00484965 Phase 4
32 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
33 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
34 Chinese PLA General Hospital Hainan Branch Unknown status NCT03602638 Phase 4 Sitagliptin;Acarbose
35 A 104-week, Open-label, Single-group Study: Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) Unknown status NCT00885872 Phase 4 Rosuvastatin (Crestor)
36 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
37 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
38 the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy Unknown status NCT03230851 Phase 4 aspirin 100mg/d therapy;aspirin 100mg/2d therapy;aspirin 100mg/3d therapy;aspirin 50mg bid therapy;aspirin 75mg/d therapy;aspirin 50mg/d therapy;indobufen 100mg bid therapy
39 Effect of Atorvastatin on Inflammatory Atherosclerotic Plaques Assessed by FDG-PET Imaging Unknown status NCT00920101 Phase 4 Atorvastatin
40 A 2-year, Open-label, Randomized Study to Evaluate the Efficacy of Rosuvastatin Dosing Adjustment by LDL-C Level Compared to That of 5mg Maintenance Dose in Chinese Patients With Carotid Atherosclerotic Plaques Unknown status NCT02532309 Phase 4 Rosuvastatin (5mg，10mg，20mg);Rosuvastatin 5mg
41 The Effect of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by T CD4+ Lymphocyte in Atherosclerotic Patients Unknown status NCT01414972 Phase 4 Vitamin A;placebo
42 Chocolate PTA Balloon Compared to Conventional Balloon Angioplasty for Sustained Lumen Gain in Below the Knee Arteries - CHOCO-CABANA Trial- Unknown status NCT04539145 Phase 4
43 A Randomized, Multicenter, Open, Parallel, Phase 4 Study to Compare the Efficacy and Safety Between High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in High ASCVD Risk Patients With Type 2 diabEtes (CREATE Study) Unknown status NCT03403556 Phase 4 Rosuvamibe;Monorova
44 In Patients Taking Protease Inhibitors Does Switching to a Bictegravir, Tenofovir Alafenamide and Emtricitabine Combination, Reduce Cardiovascular Risk: An Open-label, Randomised, Serial CT Pilot Study Unknown status NCT03986697 Phase 4 Biktarvy
45 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
46 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
47 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
48 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
49 Effects of Melatonin on Progression of Coronary Artery Calcification Unknown status NCT03966235 Phase 4 Melatonin 3 mg;Placebo
50 A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4 Cilostazol group;Probucol group;Cilostazol + Probucol group;control group

Search NIH Clinical Center for Atherosclerosis Susceptibility

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Epoprostenol
Epoprostenol Sodium
Isoxsuprine
Isoxsuprine Hydrochloride

Cochrane evidence based reviews: atherosclerosis

Sources

Genetic Tests for Atherosclerosis Susceptibility

About this section

Genetic tests related to Atherosclerosis Susceptibility:

# Genetic test Affiliating Genes
1 Atherosclerosis 28
Sources

Anatomical Context for Atherosclerosis Susceptibility

About this section

Organs/tissues related to Atherosclerosis Susceptibility:

MalaCards : Heart, Endothelial, Kidney, Bone Marrow, Smooth Muscle, Lung, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Atherosclerosis Susceptibility:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Coronary Capillary Plexus Affected by disease
2 Heart Coronary Vessels Affected by disease
3 Endothelium Arteries Arterial Endothelial Cells Affected by disease
Sources

Publications for Atherosclerosis Susceptibility

About this section

Articles related to Atherosclerosis Susceptibility:

(show top 50) (show all 33419)
# Title Authors PMID Year
1
Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. 53 62 5
14702425 2004
2
Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. 53 62 57
1731344 1992
3
Aging-related atherosclerosis is exacerbated by arterial expression of tumor necrosis factor receptor-1: evidence from mouse models and human association studies. 62 57
20421368 2010
4
Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. 62 57
9683614 1998
5
The atherogenic lipoprotein phenotype is not caused by a mutation in the coding region of the low density lipoprotein receptor gene. 62 57
9184244 1997
6
Multilocus genetic determinants of LDL particle size in coronary artery disease families. 53 57
8644718 1996
7
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. 5
10369259 1999
8
A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. 57
9683593 1998
9
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. 5
9062372 1997
10
Low-density lipoprotein subclass patterns and risk of myocardial infarction. 57
3418853 1988
11
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial. 41
36409491 2022
12
Gender differences in fasting and postprandial metabolic traits predictive of subclinical atherosclerosis in an asymptomatic Chinese population. 41
36207366 2022
13
Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. 41
36217872 2022
14
Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. 53 62
19687018 2010
15
Extracellular phospholipases in atherosclerosis. 53 62
20153800 2010
16
Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice. 53 62
20182519 2010
17
Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. 53 62
20360257 2010
18
Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. 53 62
20167662 2010
19
Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the dallas heart study. 53 62
20187767 2010
20
Associations between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. 53 62
20134100 2010
21
Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. 53 62
20444418 2010
22
Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. 53 62
20439543 2010
23
Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. 53 62
20154064 2010
24
Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. 53 62
20395699 2010
25
Soluble epoxide hydrolase in atherosclerosis. 53 62
20425256 2010
26
MMP2 genetic variation is associated with measures of fibrous cap thickness: The Atherosclerosis Risk in Communities Carotid MRI Study. 53 62
20064641 2010
27
Association between platelet endothelial cellular adhesion molecule-1 polymorphisms and atherosclerosis: results of a study on patients from northern Italy. 53 62
20370486 2010
28
Interleukin-18 gene polymorphism and markers of subclinical atherosclerosis. The Cardiovascular Risk in Young Finns Study. 53 62
20350254 2010
29
Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. 53 62
19845792 2010
30
Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. 53 62
20064818 2010
31
Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. 53 62
19896127 2010
32
Toll like receptor 4 in atherosclerosis and plaque destabilization. 53 62
19900676 2010
33
Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. 53 62
19931584 2010
34
Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. 53 62
19766217 2010
35
Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. 53 62
20110287 2010
36
Accelerated atherosclerosis in rheumatoid arthritis: rationale for mannose-binding lectins? 53 62
20197564 2010
37
[LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis]. 53 62
20146162 2010
38
Characteristics of apolipoprotein M and its relation to atherosclerosis and diabetes. 53 62
19909825 2010
39
[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis]. 53 62
20158099 2010
40
Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. 53 62
19834878 2010
41
Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. 53 62
20142250 2010
42
Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. 53 62
20145358 2010
43
Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. 53 62
20124121 2010
44
Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. 53 62
19910639 2010
45
Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages. 53 62
20137092 2010
46
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. 53 62
20078196 2010
47
Polymorphism in the IL10 promoter region and early markers of atherosclerosis: the Cardiovascular Risk in Young Finns Study. 53 62
19700159 2010
48
Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. 53 62
19851078 2010
49
A role for MMP-3 genetic variation in atherosclerosis susceptibility? 53 62
19815209 2010
50
FXR an emerging therapeutic target for the treatment of atherosclerosis. 53 62
20041971 2010
Sources

Variations for Atherosclerosis Susceptibility

About this section

ClinVar genetic disease variations for Atherosclerosis Susceptibility:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ALOX5 NG_011437.1:g.4922GGGGGC[2] MICROSAT Risk Factor
 14446 rs59439148 GRCh37: 10:45869548-45869571
GRCh38: 10:45374100-45374123
2 VEGFA, POLR1C NM_001025366.2(VEGFA):c.-2055A>C SNV Benign
 12224 rs699947 GRCh37: 6:43736389-43736389
GRCh38: 6:43768652-43768652

Copy number variations for Atherosclerosis Susceptibility from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 207754 6 160900000 164400000 Gain LPA Atherosclerosis
Sources

Expression for Atherosclerosis Susceptibility

About this section
Search GEO for disease gene expression data for Atherosclerosis Susceptibility.
Sources

Pathways for Atherosclerosis Susceptibility

About this section


Pathways directly related to Atherosclerosis Susceptibility:

# Pathway Source
1 Defective ABCG8 causes GBD4 and sitosterolemia Reactome 66

Pathways related to Atherosclerosis Susceptibility according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Plasma lipoprotein assembly, remodeling, and clearance 66
Show member pathways
 12.03 APOE APOB APOA1 ANGPTL3 ABCA1
2
Interleukin-4 and Interleukin-13 signaling 66
11.64 VCAM1 CCL2 ALOX5
3
Binding and Uptake of Ligands by Scavenger Receptors 66
Show member pathways
 11.53 APOE APOB APOA1
4
Familial hyperlipidemia type 1 74
Show member pathways
 11.34 APOB APOA1 ANGPTL3
5
Nonalcoholic fatty liver disease 74
11.1 VCAM1 INS CCL2
6
Statin inhibition of cholesterol production 74
Show member pathways
 10.81 APOE APOB APOA1 ABCA1
7
LDL Oxidation in Atherogenesis 64
10.66 VCAM1 CCL2
8
A-beta Uptake and Degradation 65
10.64 TLR4 CCL2 APOE
9
ApoE and miR-146 in inflammation and atherosclerosis 74
10.32 TLR4 APOE
Sources

GO Terms for Atherosclerosis Susceptibility

About this section

Cellular components related to Atherosclerosis Susceptibility according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 early endosome GO:0005769 9.93 VCAM1 TLR4 APOE APOB APOA1 ANGPTL3
2 high-density lipoprotein particle GO:0034364 9.8 APOE APOB APOA1
3 very-low-density lipoprotein particle GO:0034361 9.73 APOE APOB APOA1
4 intermediate-density lipoprotein particle GO:0034363 9.67 APOE APOB
5 endocytic vesicle lumen GO:0071682 9.43 APOE APOB APOA1
6 chylomicron GO:0042627 9.1 APOE APOB APOA1

Biological processes related to Atherosclerosis Susceptibility according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.08 APOE APOB APOA1 ANGPTL3 ALOX5 ABCA1
2 intermembrane lipid transfer GO:0120009 10.08 ABCA1 APOA1 APOB APOE
3 cholesterol homeostasis GO:0042632 10.07 APOE APOB APOA1 ANGPTL3 ABCA1
4 triglyceride homeostasis GO:0070328 10.03 ANGPTL3 APOA1 APOE
5 positive regulation of cholesterol efflux GO:0010875 10.02 APOE APOA1 ABCA1
6 cholesterol metabolic process GO:0008203 10.02 ABCA1 ANGPTL3 APOA1 APOB APOE
7 artery morphogenesis GO:0048844 10 APOE APOB ANGPTL3
8 reverse cholesterol transport GO:0043691 9.99 APOE APOA1 ABCA1
9 lipid transport GO:0006869 9.98 APOE APOB APOA1 ABCA1
10 phospholipid homeostasis GO:0055091 9.97 APOA1 ANGPTL3 ABCA1
11 high-density lipoprotein particle assembly GO:0034380 9.93 APOE APOA1 ABCA1
12 positive regulation of CoA-transferase activity GO:1905920 9.92 APOE APOA1
13 high-density lipoprotein particle clearance GO:0034384 9.91 APOE APOA1
14 phospholipid efflux GO:0033700 9.91 APOE APOA1 ABCA1
15 positive regulation of cholesterol metabolic process GO:0090205 9.9 APOE APOA1
16 lipoprotein catabolic process GO:0042159 9.89 APOE APOB
17 positive regulation of phospholipid efflux GO:1902995 9.88 APOE APOA1
18 regulation of Cdc42 protein signal transduction GO:0032489 9.88 APOE APOA1 ABCA1
19 positive regulation of dendritic spine maintenance GO:1902952 9.87 INS APOE
20 cholesterol efflux GO:0033344 9.86 APOE APOB APOA1 ABCA1
21 steroid metabolic process GO:0008202 9.84 APOE APOB APOA1 ABCA1
22 lipoprotein metabolic process GO:0042157 9.55 APOE APOB APOA1 ABCA1
23 positive regulation of lipid biosynthetic process GO:0046889 9.5 INS HULC APOE APOA1
24 lipoprotein biosynthetic process GO:0042158 9.17 APOE APOB APOA1 ABCA1

Molecular functions related to Atherosclerosis Susceptibility according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 10.03 TLR4 CCL2 APOE APOA1 ANGPTL3 ABCA1
2 low-density lipoprotein particle receptor binding GO:0050750 9.63 CRP APOE APOB
3 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.62 APOE APOA1
4 lipoprotein particle binding GO:0071813 9.54 APOE APOA1
5 lipid transporter activity GO:0005319 9.43 APOE APOB APOA1 ABCA1
6 cholesterol transfer activity GO:0120020 9.23 APOE APOB APOA1 ABCA1
Sources

Sources for Atherosclerosis Susceptibility

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....